Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Charles River Laboratories Intl (CRL)
NYSE:CRL
Holding CRL?
Track your performance easily
CRL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$161.65 - $275.00
Previous Close$205.27
Volume595.20K
Average Volume (3M)646.93K
Market Cap
$10.60B
Enterprise Value$13.31B
Total Cash (Recent Filing)$179.21M
Total Debt (Recent Filing)$2.84B
Price to Earnings (P/E)24.3
Beta1.29
Next Earnings
Oct 30, 2024EPS Estimate
$2.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.46
Shares Outstanding51,630,726
10 Day Avg. Volume698,660
30 Day Avg. Volume646,928
Standard Deviation0.10
R-Squared0.47
Alpha-0.00076
Financial Highlights & Ratios
Price to Book (P/B)-66.17
Price to Sales (P/S)2.55
Price to Cash Flow (P/CF)13.40
P/FCF Ratio16.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.26
Enterprise Value/Gross Profit8.86
Enterprise Value/Ebitda15.23
Forecast
1Y Price Target
$221.00Price Target Upside7.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Charles River Labs News
Bulls Say, Bears Say
Bulls Say
Competitive PositionIndustry checks on CRL were overwhelmingly positive and the company boasts a solid reputation among customers, known for its therapeutic expertise, high quality, its global footprint, and regulatory experience.
EarningsCharles River delivered a solid EPS beat ($2.80 vs street estimates of $2.40) on lower opex on modest top line leverage.
Growth PotentialManagement has done an impressive job building out a diversified services business across all aspects of preclinical drug discovery and adding manufacturing capabilities in high-growth.
Bears Say
EarningsCharles River's cut to 2024 guidance is slightly deeper than buy side expectations.
Financial PerformanceCRL reported a 2Q top- and bottom-line beat but took down guidance substantially due to an unexpectedly weaker demand environment in DSA.
Market TrendsThere is a marked shift in large pharma drug development spending toward clinical vs. preclinical assets, with little visibility as to when that will improve.
---
Ownership Overview
2.74% Insiders
35.20% Mutual Funds
58.08% Other Institutional Investors
3.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRL FAQ
What was Charles River Laboratories Intl’s price range in the past 12 months?
Charles River Laboratories Intl lowest stock price was $161.65 and its highest was $275.00 in the past 12 months.
What is Charles River Laboratories Intl’s market cap?
Currently, no data Available
When is Charles River Laboratories Intl’s upcoming earnings report date?
Charles River Laboratories Intl’s upcoming earnings report date is Oct 30, 2024 which is in 66 days.
How were Charles River Laboratories Intl’s earnings last quarter?
Charles River Laboratories Intl released its earnings results on Aug 07, 2024. The company reported $2.8 earnings per share for the quarter, beating the consensus estimate of $2.394 by $0.406.
Is Charles River Laboratories Intl overvalued?
According to Wall Street analysts Charles River Laboratories Intl’s price is currently Undervalued.
Does Charles River Laboratories Intl pay dividends?
Charles River Laboratories Intl does not currently pay dividends.
What is Charles River Laboratories Intl’s EPS estimate?
Charles River Laboratories Intl’s EPS estimate is $2.42.
How many shares outstanding does Charles River Laboratories Intl have?
Charles River Laboratories Intl has 51,630,726 shares outstanding.
What happened to Charles River Laboratories Intl’s price movement after its last earnings report?
Charles River Laboratories Intl reported an EPS of $2.8 in its last earnings report, beating expectations of $2.394. Following the earnings report the stock price went down -12.605%.
Which hedge fund is a major shareholder of Charles River Laboratories Intl?
Among the largest hedge funds holding Charles River Laboratories Intl’s share is Ariel Investments LLC. It holds Charles River Laboratories Intl’s shares valued at 187M.
---
Charles River Labs Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$221.00 (7.66% Upside)
$221.00 (7.66% Upside)
Blogger Sentiment
Bullish
CRL Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 57.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $354.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.55%
12-Months-Change
Fundamentals
Return on Equity
12.54%
Trailing 12-Months
Asset Growth
2.26%
Trailing 12-Months
Company Description
Charles River Laboratories Intl
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client's use of research models in screening non-clinical drug candidates. The Discovery & Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment provides endotoxin and microbial detection, avian vaccine and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.
---
CRL Company Deck
---
CRL Earnings Call
Q2 2024
0:00 / 0:00
---
CRL Revenue Breakdown
63.34% DSA
19.19% RMS
17.47% Manufacturing
---
CRL Stock 12 Month Forecast
Average Price Target
$221.00
▲(7.66% Upside)
Technical Analysis
Best Analysts Covering CRL
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+44.08%
reiterated a buy rating 6 months ago
Copying Dan Leonard's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +44.08% per trade.
---